The current role of stem cell transplantation in MPNs & how this may change with novel agents

Myeloproliferative neoplasms (MPNs) represent a heterogeneous group of diseases which remain a challenge to treat. While there have been several advances in the MPN treatment landscape, allogeneic stem cell transplantation (alloSCT) remains the only curative option for patients. There are several important factors to consider when selecting patients for transplant, and the introduction of novel targeted therapies may further impact the role of alloSCT in MPNs.

In this podcast, you will hear from Ruben Mesa, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, Jeanne Palmer, MD, Mayo Clinic, Phoenix, AZ, Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, and Haris Ali, MD, City of Hope, Duarte, CA, who discuss the current role of alloSCT in MPNs and how this may change with novel agents.

The post The current role of stem cell transplantation in MPNs & how this may change with novel agents appeared first on VJHemOnc.